Listen on:
Episodes
7 days ago
7 days ago
The diagnostic landscape for rare disease is being reshaped by whole exome sequencing, which is increasingly used as a first-line test for cases involving unexplained developmental delay, epilepsy, or multisystem disease. In this episode, Rebecca Johnson Wheeler, MS, CGC, explores how whole exome sequencing and Quest Diagnostics genetic experts are transforming rare disease diagnosis by enabling earlier answers, reducing unnecessary testing, and improving care for patients and families.
This episode will
Describe whole exome sequencing in rare disease (1:40)
Review clinical indications and guidelines for whole exome sequencing, including the available test options (3:25)
Explain the role of genetic counselors in supporting rare disease and whole exome sequencing (5:50)
Date: May 2026
Speaker(s): Rebecca Johnson Wheeler, MS, CGC
Contributor(s): Rebecca Johnson Wheeler, MS, CGC; Maeson Latsko, PhD; Meenakshi Mahey Kumar, MS, CGC; Natalie Cuttic; Whitney Dodge, MS, CGC; Khalida Liaquat, MS, CGC
Additional resources:
Quest Diagnostics Clinical Education Center [Link]
Test information: https://www.questdiagnostics.com/healthcare-professionals/about-our-tests/genetics/exome
Blog: https://www.questdiagnostics.com/our-company/actions-insights/2026-blogs/considering-mitochondrial-genomes-in-whole-exome-testing
Ordering information:
Whole Exome | Test Detail | Quest Diagnostics
Whole Exome Family Trio | Test Detail | Quest Diagnostics
Whole Exome Family Duo | Test Detail | Quest Diagnostics
References:
Reinholdt L, Chesler E, Pera M, Rosenthal N. The rare-to-common disease journey: a winding road to new therapies. Trends Genet. 2025;41(9):762-773. doi:10.1016/j.tig.2025.05.003
Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(11):2029-2037. doi:10.1038/s41436-021-01242-6
Smith L, Malinowski J, Ceulemans S, et al. Genetic testing and counseling for the unexplained epilepsies: An evidence-based practice guideline of the National Society of Genetic Counselors. J Genet Couns. 2023;32(2):266-280. doi:10.1002/jgc4.1646
Rodan LH, Stoler J, Chen E, Geleske T; Council on Genetics . Genetic Evaluation of the Child With Intellectual Disability or Global Developmental Delay: Clinical Report. Pediatrics. 2025;156(1):e2025072219. doi:10.1542/peds.2025-072219Ewans
LJ, Minoche AE, Schofield D, et al. Whole exome and genome sequencing in mendelian disorders: a diagnostic and health economic analysis. Eur J Hum Genet. 2022;30(10):1121-1131. doi:10.1038/s41431-022-01162-2
van de Kamp JM, Betsalel OT, Mercimek-Mahmutoglu S, et al. Phenotype and genotype in 101 males with X-linked creatine transporter deficiency. J Med Genet. 2013;50(7):463-472. doi:10.1136/jmedgenet-2013-101658
Dunbar M, Jaggumantri S, Sargent M, Stockler-Ipsiroglu S, van Karnebeek CD. Treatment of X-linked creatine transporter (SLC6A8) deficiency: systematic review of the literature and three new cases. Mol Genet Metab. 2014;112(4):259-274. doi:10.1016/j.ymgme.2014.05.011
Monday May 04, 2026
Monday May 04, 2026
More than 80% of patients with celiac disease remain undiagnosed or misdiagnosed. In this episode, Maeson Latsko, PhD, explores the reasons for the diagnostic odyssey in celiac disease, from the disease’s wide range of symptoms to common pitfalls in testing. Celiac disease triggers a specific autoimmune response where the body attacks its own small intestines after gluten exposure, leading to malabsorption and comorbid conditions. Providers can screen for celiac disease using a serologic panel that detects key autoantibodies like tTG-IgA and accounts for IgA deficiency.
This episode will
Describe the autoimmune mechanism in celiac disease, including the role of tissue transglutaminase (tTG) and the HLA-DQ2/DQ8 genetic predisposition (2:00)
Identify the key serologic markers used for diagnosis, including tTG-IgA, endomysial antibody (EMA), and the purpose of IgG-based backup tests for patients with IgA deficiency (2:40)
Outline the clinical pathway for diagnosis, from initial testing with an automated reflex panel to the role of gut biopsy and follow-up monitoring (5:10)
To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: May 2026
Speaker(s): Maeson Latsko, PhD
Contributor(s): Maeson Latsko, PhD; Frank Samarro; Adrienne Uzonyi; Aixa Santos; Trisha Winchester, PhD;
Additional Resources:
Quest Diagnostics Clinical Education Center [Link]
Celiac Disease Comprehensive Panel with Gliadin Antibody (IgG) | Test Detail | Quest Diagnostics
HLA Typing for Celiac Disease | Test Detail | Quest Diagnostics
Tissue Transglutaminase (tTG) Antibody (IgA) | Test Detail | Quest Diagnostics
IgA | Test Detail | Quest Diagnostics
Gliadin (Deamidated) Antibody (IgA) | Test Detail | Quest Diagnostics
References:
Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. ACG Clinical Guidelines: Diagnosis and Management of Celiac Disease. Am J Gastroenterol. 2013;108(5):656-676.
Fasano A, Catassi C. Celiac Disease. N Engl J Med. 2012;367(25):2419-2426.
Hill ID, Dirks MH, Liptak GS, et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2005;40(1):1-19.
Celiac Disease Foundation. Celiac Disease Facts and Figures. Accessed April 15, 2026.
Monday Apr 13, 2026
Monday Apr 13, 2026
More than 36 million Americans are living with type 2 diabetes, and an estimated 30%-50% of patients remain uncontrolled. In this episode, Maeson Latsko, PhD, explores an under-recognized contributor to difficult-to-control diabetes: hypercortisolism. Hypercortisolism disrupts glucose metabolism and insulin function, leading to elevated HbA1c that isn’t as responsive to traditional treatment. Providers can screen for hypercortisolism using an overnight dexamethasone suppression test.
This episode will
Review the clinical characteristics of difficult-to-control diabetes and when hypercortisolism should be considered (1:00)
Explain how hypercortisolism contributes to type 2 diabetes (2:25)
Outline the clinical approach to screening for hypercortisolism (4:50)
To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: April 2026
Speaker(s): Maeson Latsko, PhD
Contributor(s): Maeson Latsko, PhD; Trisha Winchester, PhD; Gregory Buchan, PhD; Sanjay Dixit, MD
Additional Resources
Quest Diagnostics Clinical Education Center [Link]
Hypercortisolism in Difficult-To-Control Type II Diabetes | Quest Diagnostics
Ordering information:
Dexamethasone Suppression Test (DST), 1 Specimen | Test Detail | Quest Diagnostics
Dexamethasone | Test Detail | Quest Diagnostics
Monday Mar 30, 2026
Monday Mar 30, 2026
Cervical cancer is the fourth most common cancer in women globally, and Human papilloma virus (HPV) causes nearly all cases. Laboratory screening can detect infection or abnormal cells early, so clinicians can intervene before cancer develops. Screening options include Pap testing, HPV testing, and co-testing, and guidelines recommendation different combinations of these tests based on age and clinical presentation.
This episode will
Explain what HPV testing is and why HPV drives nearly all cervical cancers (1:00)
Compare Pap testing, HPV testing, and co-testing (2:00)
Summarize guideline-based screening options by age (3:30)
To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: March 2026
Speaker(s): Maeson Latsko, PhD
Contributor(s): Maeson Latsko, PhD; Trisha Winchester, PhD, MBA; Pat Alagia, MD, MBA; Lisa Smith; Paula McCollem
Additional Resources
Quest Diagnostics Clinical Education Center [Link]
Quest Diagnostics Cervical Cancer Portfolio Brochure
ASCCP Management Guidelines Web Application
Ordering information:
ThinPrep Automated Test Code Aid
Age 21-29
Pap alone
ThinPrep® Automated Pap | Test Detail | Quest Diagnostics
Pap reflex to HPV DNA
ThinPrep® Automated Pap Reflex HPV DNA (16,18,Other High Risk) PCR,Cervical | Test Detail | Quest Diagnostics
Pap reflex to HPV mRNA
ThinPrep® Automated Pap with Reflex to HPV mRNA E6/E7 | Test Detail | Quest Diagnostics
Age 30-65
Pap and HPV DNA
ThinPrep® Automated Pap and HPV DNA (16, 18, Other High Risk) PCR, Cervical | Test Detail | Quest Diagnostics
Pap and HPV mRNA reflex to genotypes 16, 18/45
ThinPrep® Automated Pap and HPV mRNA E6/E7 with Reflex to HPV 16,18/45 | Test Detail | Quest Diagnostics
HPV Primary reflex to Pap
HPV DNA (16,18, Other High Risk), PCR with Reflex to ThinPrep® Automated Pap | Test Detail | Quest Diagnostics
HPV Self-Collection
HPV DNA (16, 18, Other High Risk), PCR, Vaginal Self-Collected | Test Detail | Quest Diagnostics
Monday Mar 16, 2026
Monday Mar 16, 2026
Chronic kidney disease (CKD) is a major healthcare crisis, impacting about 35 million people in the US. In this episode, Maeson Latsko, PhD and Ines Dahne discuss end-stage kidney disease management in a nephrology setting, and how Quest Diagnostics is providing continuity of care for patients across primary care, nephrology, dialysis, hospitals, and transplant settings.
This episode will
Explain the nephrologist’s role in managing complex CKD patients across clinics, dialysis centers, and hospitals (3:00)
Discuss how the strategic Fresenius–Quest Diagnostics partnership will ensure business and medical continuity for nephrologists and their patients (8:15)
Describe the frequency of lab monitoring in nephrology, and how this partnership will support broader testing and to help manage cardiometabolic and autoimmune comorbidities and reinforce prevention given low CKD awareness (14:40)
To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: March 2026
Speaker(s): Maeson Latsko, PhD; Ines Dahne
Contributor(s): Maeson Latsko, PhD; Ines Dahne; Trisha Winchester, PhD; Millicent Kee, MSN, FNP-BC; Rohit Joshi; Nathan Adamo; Mouris Saghir, PhD
Additional Resources
Quest Diagnostics Clinical Education Center [Link]
Monday Mar 02, 2026
Monday Mar 02, 2026
Approximately 55 million people have dementia. Alzheimer’s disease (AD) is the most common form of dementia, impacting nearly 7 million Americans. Blood-based biomarkers such as the beta amyloid 42/40 ratio and phosphorylated tau (p-tau217) are now providing earlier and more accessible insights into Alzheimer's pathology. These markers help differentiate Alzheimer's from other dementias, support early intervention, and improve diagnostic confidence. The Quest Diagnostics panel combines these biomarkers to generate a highly accurate likelihood score for Alzheimer's pathology, enhancing clinical decision-making and care planning.
This episode will
Describe the pathology of AD (2:00)
Summarize the role of blood-based biomarkers in the evaluation of suspected AD (3:00)
Explain how biomarkers can support patient evaluation and help clinical decision-making (6:30)
To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: March 2026
Speaker(s): Maeson Latsko, PhD
Contributor(s): Maeson Latsko, PhD; Trisha Winchester, PhD; Amanda Backner; Kenneth French; Michael Prouse, PhD; Mouris Saghir, PhD; Matthew Stroh, PhD; Michael Racke, MD
Additional Resources
Quest Diagnostics Clinical Education Center [Link]
Test Summary: AD Detect
FAQ: AD Detect
Ordering information:
AD-Detect™ ABeta 42/40 and p-tau217 Evaluation, Plasma
References:
Alzheimer's Association. Alzheimer’s Disease Facts and Figures. Alzheimer’s Disease and Dementia. Published 2025. https://www.alz.org/alzheimers-dementia/facts-figures
World Health Organization. Dementia. World Health Organization. Published March 31, 2025. https://www.who.int/news-room/fact-sheets/detail/dementia
Palmqvist S, Whitson HE, Allen LA, et al. Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimers Dement. 2025;21(7):e70535. doi:10.1002/alz.70535
Monday Feb 09, 2026
Monday Feb 09, 2026
Pharmacogenetics (PGx) testing is a field that can transform how clinicians select and dose medications by accounting for individual genetic variability in drug metabolism, transport, and response. In this episode, Maeson Latsko, PhD, and Kathleen O’Brien, CGC, DABMG, discuss the clinical utility of PGx testing and how providers can integrate it into routine care.
This episode will
Describe pharmacogenetics (PGx) testing (2:45)
Review different types of pharmacogenes and their clinical utility (12:15)
Walk through Quest Diagnostics PGx test offerings (16:30)
To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: February 2026
Speaker(s): Maeson Latsko, PhD; Kathleen O’Brien, CGC, DABMG
Contributor(s): Maeson Latsko, PhD; Kathleen O’Brien, CGC, DABMG; Rebecca Johnson, CGC; Trisha Winchester, PhD; Millicent Kee, MSN, FNP-BC
Additional Resources
Quest Diagnostics Clinical Education Center [Link]
Test summary: Pharmacogenomics
Ordering information:
Pharmacogenomics Panel with Coriell Life Sciences (CLS) Report | Test Detail | Quest Diagnostics
Pharmacogenomics Panel | Test Detail | Quest Diagnostics
References:
Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. Journal of Internal Medicine. 2001;250(3):186-200. doi:10.1046/j.1365-2796.2001.00879.x
Chanfreau-Coffinier C, Hull LE, Lynch JA, et al. Projected prevalence of actionable pharmacogenetic variants and level a drugs prescribed among US veterans health administration pharmacy users. JAMA Netw Open. 2019;2(6):e195345. doi:10.1001/jamanetworkopen.2019.5345
Swen JJ, van der Wouden CH, Manson LE, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet (London, England). 2023;401(10374):347-356. Doi:10.1016/S0140-6736(22)01841-4
Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903
Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668
Oslin DW, Lynch KG, Shih MC, et al. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA. 2022;328(2):151-161. doi:10.1001/jama.2022.9805
Bradley P, Shiekh M, Mehra V, et al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility. J Psychiatr Res. 2018;96:100-107. doi:10.1016/j.jpsychires.2017.09.024
Greden JF, Parikh SV, Rothschild AJ, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019;111:59-67. doi:10.1016/j.jpsychires.2019.01.003
Swen JJ, van der Wouden CH, Manson LE, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401(10374):347-356. doi:10.1016/S0140-6736(22)01841-4
Monday Jan 26, 2026
Monday Jan 26, 2026
In this special episode of Healthier World designed to give you Instant Insights, Dr Maeson Latsko discusses the critical role of inflammation in cardiovascular events, focusing on the importance of high-sensitivity C-reactive protein (hsCRP) levels. Cardiovascular events often stem from the rupture of soft plaque, which is fueled by inflammation. Hs-CRP can be used to gauge cardiovascular risk, above even when LDL-C is considered normal. Hs-CRP should be thought of as a red flag for chronic conditions that increase risk for CVD, such as metabolic syndrome, diabetes, and hypertension, emphasizing the importance of addressing inflammation to prevent heart attacks and strokes.
This episode will
Differentiate hs-CRP from general CRP levels in the context of acute and chronic inflammation (1:10)
Introduce hs-CRP as a critical biomarker for assessing cardiovascular risk (1:50)
Highlight the integration of hs-CRP into cardiovascular prevention guidelines (5:00)
To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 1/2026
Speaker(s): Maeson Latsko, PhD
Contributor(s): Maeson Latsko, PhD; Trisha Winchester, PhD; Millicent Kee, MSN, FNP-BC; Mouris Saghir, PhD
Additional Resources:
Quest Diagnostics Clinical Education Center [Link]
Test summary: hs-CRP
Ordering information:
Hs-CRP | Test Detail | Quest Diagnostics
References:
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377 (12):1119-1131. doi:10.1056/NEJMoa1707914
Singh TP, Morris DR, Smith S, et al. Systematic review and meta-analysis of the association between C-reactive protein and major cardiovascular events in patients with peripheral artery disease. Eur J Vasc Endovasc Surg. 2017;54 (2):220-233. doi:10.1016/j.ejvs.2017.05.009
Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23 (suppl 2):1-87. doi:10.4158/EP171764.APPGL
US Preventive Services Task Force. Risk assessment for cardiovascular disease with nontraditional risk factors: US Preventive Services Task Force recommendation statement. JAMA. 2018;320 (3):272-280. doi:10.1001/jama.2018.8359
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139 (25):e1082-e1143. doi:10.1161/CIR.0000000000000625
Ridker PM, Bhatt DL, Pradhan AD, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. 2023;401(10384):1293-1301. doi:10.1016/S0140-6736(23)00215-5
Alam M, Kontopantelis E, Mamas MA, et al. Meta-analysis of the effect of colchicine on C-reactive protein in patients with acute and chronic coronary syndromes. Coron Artery Dis. 2023;34(3):210-215. doi:10.1097/MCA.0000000000001220
Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107 (3):499-511. doi:10.1161/01.cir.0000052939.59093.45
Monday Jan 05, 2026
Monday Jan 05, 2026
Metabolic dysfunction is a common root cause of many cardiometabolic conditions that burden the healthcare system. This episode will address insulin resistance, a syndrome that underlies metabolic dysfunction, and how tools can catch risk early, allowing actions that may prevent and reverse the onset of chronic illness. Today’s episode is with Quest Diagnostics experts Kenneth French, Senior Clinical Consultant, and Maeson Latsko, PhD, Clinical and Education Specialist.
This episode will
Identify how early identification of insulin resistance can prevent the rise in metabolic dysfunction and Type II Diabetes (3:00)
Describe the insulin resistance panel with score (8:11)
Elucidate how identifying insulin resistance can prevent other chronic illness, such as liver related disorders and kidney disease (12:41)
The content was current as of the time of recording. To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 09/2024
Speaker(s): Kenneth French; Maeson Latsko, PhD
Contributor(s): Maeson Latsko, PhD; Trisha Winchester, PhD; Kenneth French
Additional Resources:
Podcast: Action from Insight: Tackling Insulin Resistance (18 min)
Webinar: Early Identification of Type 2 Diabetes Risk for the Primary Care Setting
Ordering information:
Insulin Resistance Panel with Score | Test Detail | Quest Diagnostics
Insulin Resistance Panel with Score | Test Summary | Quest Diagnostics
References:
Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med. 2019;381(25):2440-2450. doi:10.1056/NEJMsa1909301
Abbasi F, Shiffman D, Tong CH, et al. Insulin resistance probability scores for apparently healthy individuals. J Endocr Soc. 2018;2(9):1050-1057. doi:10.1210/js.2018-00107
Bril F, McPhaul MJ, Kalavalapalli S, et al. Intact fasting insulin identifies nonalcoholic fatty liver disease in patients without diabetes. J Clin Endocrinol Metab. 2021;106(11):e4360-e4371. doi:10.1210/clinem/dgab417
Healy, M. By 2030, nearly half of all U.S. adults will be obese, experts predict. New York Times. https://www.latimes.com/science/story/2019-12-18/nearly-half-of-us-adults-will-be-obese-by-2030
Khan RMM, Chua ZJY, Tan JC, et al. From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research. Medicina (Kaunas). 2019;55(9):546. doi:10.3390/medicina55090546
Monday Dec 22, 2025
Monday Dec 22, 2025
The holidays are a time of celebration, but they can also be a challenging time to maintain heart-healthy habits. In today’s episode, Maeson Latsko, PhD and Patty Bianchi, MS, RDN discuss how disrupted routines, rich foods, and elevated stress can impact well-being. We discuss realistic, evidence-based ways to enjoy the holidays while supporting cardiometabolic health.
This episode will
Discuss common challenges faced during the holiday season (2:15)
Review ways to avoid holiday weight gain (5:42)
Provide practical tips to enjoy the holiday season while supporting your physical health, mental health and well-being (15:10)
To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: December 2025
Speaker(s): Maeson Latsko, PhD; Patty Bianchi, MS, RDN
Contributor(s): Maeson Latsko, PhD; Patty Bianchi, MS, RDN; Trisha Winchester, PhD; Millicent Kee, MSN, FNP-BC
Additional Resources
Quest Diagnostics Clinical Education Center [Link]